Read more

September 30, 2021
1 min watch
Save

VIDEO: Efficacy shown, toxicity a factor for DS-7300

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses a phase I/II multicenter first-in-human trial of DS-7300, an anti-B7-H3, which was studied in patients with advanced solid tumors.

"There was efficacy shown, just like with the MGC018, though the toxicity is going to be a key factor of applicability of the agent into clinical practice," Shenderov said.